CompanyGraph
Shenzhen New Industries Biomedical Engineering Co., Ltd.
300832 · SZSE · China
snibe.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $6.26B, above the global median of $1.15B
- PositionOperating margin is 37%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.24%Above 5Y avg (1.63%)
Annual Rate
CNY 1.20Paid annual
Payout Ratio
54.9%Sustainable
Payback Period
43.2 yr
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
42.16BCNY6.26B · vs all stocks (USD)
Trailing P/E
24.50xvs Medical Devices peers
Revenue (TTM)
4.81BCNY714.71M · vs all stocks (USD)
Profit Margin
35.68%vs Medical Devices peers
Beta
-0.3050xvs all stocks
52-Week Change
-9.98%vs all stocks
Market Capitalization
42.16BCNY6.26B · vs all stocks (USD)
Enterprise Value
38.75BCNY5.76B · vs all stocks (USD)
Trailing P/E
24.50xvs Medical Devices peers
Forward P/E
19.12xvs Medical Devices peers
Price to Sales (TTM)
8.76xvs Medical Devices peers
Price to Book (MRQ)
4.70xvs Medical Devices peers
Enterprise to Revenue
8.05xvs Medical Devices peers
Enterprise to EBITDA
18.14xvs Medical Devices peers
Gross Margin
73.48%vs Medical Devices peers
Profit Margin
35.68%vs Medical Devices peers
Operating Margin
36.98%vs Medical Devices peers
Return on Assets (TTM)
12.99%vs Medical Devices peers
Return on Equity (TTM)
19.87%vs Medical Devices peers
Revenue (TTM)
4.81BCNY714.71M · vs all stocks (USD)
Revenue per Share (TTM)
6.13CNYUpdated Aug 20, 2026Quarterly Revenue Growth
21.80%vs Medical Devices peers
Gross Profit (TTM)
3.39BCNY503.46M · vs all stocks (USD)
EBITDA (TTM)
1.88BCNY279.32M · vs all stocks (USD)
Net Income (TTM)
1.72BCNY254.99M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
27.60%vs Medical Devices peers
Operating Cash Flow (TTM)
1.96BCNY291.41M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.29BCNY191.15M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.20CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.24%vs all stocks
5-Year Average Dividend Yield
1.63%vs all stocks
Payout Ratio
54.88%vs Medical Devices peers
Revenue
4.58BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.41BCNYFY2025 · Dec 31, 2025Gross Profit
3.17BCNYFY2025 · Dec 31, 2025Operating Income
1.81BCNY268.44M · vs all stocks (USD)
Pre-tax Income
1.86BCNYFY2025 · Dec 31, 2025Income Tax Expense
235.01MCNYFY2025 · Dec 31, 2025Net Income
1.62BCNYFY2025 · Dec 31, 2025EBIT
1.86BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.06BCNYFY2025 · Dec 31, 2025Research & Development
477.77MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
301.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
53.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
36.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
530.51KCNYFY2025 · Dec 31, 2025EPS (Basic)
2.06CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.06CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
785.73MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
785.73MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.62BCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.59BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.28BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
996.03MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.62BCNYFY2025 · Dec 31, 2025Other Non-cash Items
77.40MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-226.16MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
115.56MCNYFY2025 · Dec 31, 2025Capital Expenditures
-311.40MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.66BCNYFY2025 · Dec 31, 2025Sale of Investments
2.56BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-413.40MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.02BCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.61MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.03BCNYFY2025 · Dec 31, 2025Shares Outstanding
785.72MSharesUpdated Aug 20, 2026Float Shares
329.14MSharesUpdated Aug 20, 2026% Held by Insiders
48.54%vs all stocks
% Held by Institutions
23.17%vs all stocks
Total Cash (MRQ)
3.41BCNY506.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.34CNYUpdated Aug 20, 2026Total Debt (MRQ)
3.30MCNY490.50K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0004xvs Medical Devices peers
Current Ratio (MRQ)
9.13xvs Medical Devices peers
Book Value per Share (MRQ)
11.41CNYUpdated Aug 20, 2026Total Assets
9.94BCNY1.48B · vs all stocks (USD)
Total Current Assets
5.69BCNYFY2025 · Dec 31, 2025Total Liabilities
795.91MCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.25BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
162.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
633.89MCNYFY2025 · Dec 31, 2025Cash
996.03MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.41MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
997.44MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.27BCNYFY2025 · Dec 31, 2025Accounts Receivable
989.99MCNYFY2025 · Dec 31, 2025Inventory
1.04BCNYFY2025 · Dec 31, 2025Accounts Payable
152.11MCNYFY2025 · Dec 31, 2025Short-term Debt
1.82MCNYFY2025 · Dec 31, 2025Other Current Liabilities
8.00MCNYFY2025 · Dec 31, 2025Long-term Debt
1.86MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.76MCNYFY2025 · Dec 31, 2025Common Stock (Book)
785.72MCNYFY2025 · Dec 31, 2025Retained Earnings
6.62BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
9.14BCNY1.36B · vs all stocks (USD)
52-Week Low
37.50CNYUpdated Aug 20, 202652-Week High
71.51CNYUpdated Aug 20, 202652-Week Change
-9.98%vs all stocks
Beta
-0.3050xvs all stocks
50-Day MA
45.33CNYUpdated Aug 20, 2026200-Day MA
51.41CNYUpdated Aug 20, 2026Avg 10-Day Volume
10.08MSharesUpdated Aug 20, 2026Avg 30-Day Volume
8.47MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
2.19CNYUpdated Aug 20, 202612 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 37%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.37Industry median: 0.07Industry P95: 0.37Peers compared: 59.00
Profit margin is 35.7%, higher than 95% of its Medical Devices peers (median 3.6%)Significant
Profit margin: 0.36Industry median: 0.04Industry P95: 0.31Peers compared: 59.00
Return on equity is 19.9%, higher than 95% of its Medical Devices peers (median 2.8%)Significant
Return on equity: 0.20Industry median: 0.03Industry P95: 0.18Peers compared: 59.00
Current ratio is 9.13×, higher than 95% of its Medical Devices peers (median 2.76×)Significant
Current ratio: 9.13Industry median: 2.76Industry P95: 8.20Peers compared: 59.00
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.21×)Notable
Debt-to-equity: 0.00Industry median: 0.21Industry P5: 0.00Peers compared: 59.00
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.66
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $6.26B, above the global median of $1.15BNotable
Market cap (USD): 6,261,851,228.846Global Median: 1,146,734,693.424
Revenue is $714.71M, above the global median of $520.53MNotable
Revenue (USD): 714,705,577.185Global Median: 520,528,949.311
Levered free cash flow is $191.15M, above the global median of $16.24MNotable
Levered free cash flow (USD): 191,148,462.29Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Bochuan Electronic Co., Ltd.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity ConfigurationMulti-Year FCF With Growth And Margin
Classys Inc.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Pharma Research Products Co., Ltd
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin